Skip to content

VISIOMED GROUP – Success of the participatory bond issue launched by Visiomed Group which reaches 2.5 M EUR in subscription in 16 days – 07/29/2022 – 07:30


Success of the participatory bond issue launched by Visiomed Group which reached €2.5 million in subscription in 16 days

Paris, July 29, 2022

VISIOMED GROUP (FR0013481835 – ALVMG), a group dedicated to innovative health technologies and services, announces that it reached yesterday, i.e. in just 16 days, the first objective of €2.5 million in subscriptions for its participatory bond. Subscription remains open until August 15, 2022.

Thomas Picquette, Managing Director of VISIOMED GROUP declares: “I would like to thank all the subscribers for their trust in VISIOMED GROUP and in the strategic direction we have chosen. This is an important date in the history of the group and the success of this bond issue open to the public shows the strong evolution of the company in this year 2022: we are financeable, we are now working with a policy structured in according to the needs of our subsidiaries and our strategic plan, non-dilutive, and we put it in place quickly! We now intend to go as high as possible, each additional subscription will allow us to accelerate even more. »

As a reminder, the bond issue authorized by the Board of Directors of VISIOMED GROUP on July 11, 2022, is accessible to the general public on the participatory platform Equisafe Invest. until August 15, 2022 (

VISIOMED GROUP will rely on this financing to pursue its development strategy as presented in its plan of May 25, 2022[1] and during the hosted webinar on June 29, 2022[2]while respecting its commitments to use non-dilutive sources of financing:

  • The acceleration of the expansion of Smart Salem with in particular the announcement of the signature of the framework contract with the Dubai Health Authority (DHA) for the opening of its 3th center[3] ;
  • The repositioning of BewellConnect;
  • Activation of synergies and external growth opportunities.

The bonds, with a nominal unit value of €1.00, will have a maturity of 2 years, will be ultimately redeemable at par and carry an annual interest rate of 10.5% payable on each anniversary. The amount of the issue may reach €5 million. The subscription period runs from July 12, 2022 12:00 p.m. to August 15, 2022 11:59 p.m.

All information and access to the bond subscription form are available on the Equisafe Invest website, a platform registered as a Participatory Investment Advisor by ORIAS:


This issue will not give rise to a Prospectus approved by the AMF.

Risk factors

The attention of the public is drawn to the risk factors relating to the company and its activity, described in the 2021 Annual Financial Report available on the Company’s website ( The realization of all or part of these risks is likely to have an unfavorable effect on the activity, the financial situation, the results, the development or the prospects of the company.


Founded in 2007, VISIOMED GROUP develops and markets innovative health products and services focused on uses. Its mission: to put innovation at the service of the health of all, starting from the needs of each one. BewellConnect®, its connected health subsidiary, today concentrates all the know-how of VISIOMED GROUP in terms of e-health for the general public as well as for players in the world of health with a complete ecosystem of solutions that improve prevention. , treatment and medical follow-up. It has developed and markets in particular VisioCheck®the 1time mobile and connected teleconsultation station weighing less than 300 grams.

In August 2021, VISIOMED GROUP acquired Smart Salem (, the only medical center digitized and accredited by the Dubai Ministry of Health (DHA) as well as the General Directorate of Residence and Foreign Affairs (GDRFA) in the United Arab Emirates.

Based in Paris, VISIOMED GROUP is listed on Euronext Growth (ALVMG). More information on and


Investor Relations Financial Press Relations
Phone: 01 53 67 36 78 Tel: 01 53 67 36 34

© Visiomed Group SA 2022. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.


This release contains non-factual materials, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current view and assumptions of the Company’s management. They incorporate known and unknown risks and uncertainties that could cause actual results, profitability and expected events to differ materially. Furthermore, VISIOMED GROUP, its shareholders and its respective affiliates, directors, officers, counsel and employees have not verified the accuracy of, and make no representations or warranties about, the statistical information or the forward-looking information contained in this release that are or are derived from third party sources or industry publications. These statistical data and forward-looking information are used in this press release for informational purposes only.

[1] Link to the presentation:

[2] Link to the replay:

[3] Smart Salem: signature of the framework contract with the Dubai Health Authority (DHA) for the opening of the 3rd center


Leave a Reply

Your email address will not be published.